1 |
Twycross R. Greaves MW, Handwerker H, Jones EA, Libretto SE, Szepietowski JC, Zylicz Z. Itch: scratching more than the surface. QJM 2003; 96: 7-26.
DOI
|
2 |
Wahgren CF. Itch and atopic dermatitis: clinical and experimental studies. Acta Derm Venereol Suppl (Stockh) 1991; 165: 1-53.
|
3 |
Wallengren J. Neuroanatomy and neurophysiology of itch. Dermatol Ther 2005; 18: 292-303.
DOI
ScienceOn
|
4 |
Tobin D, Nabarro G, Baart de la Falle H, van Vloten WA, van der Putte SC, Schuurman HJ. Increased number of immunoreactive nerve fibers in atopic dermatitis. J Allergy Clin Immunol 1992; 90: 613-622.
DOI
|
5 |
Torgovnick J, Arsura E, Sethi NK, Hu CJ, Yuan RY, Sheu JJ, Apfel SC. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial: botulinum toxin for neuropathic pain? Neurology 2010; 74: 92-93.
DOI
ScienceOn
|
6 |
Swartling C, Naver H, Lindberg M, Anveden I. Treatment of dyshidrotic hand dermatitis with intradermal botulinum toxin. J Am Acad Dermatol 2002; 47: 667-671.
DOI
ScienceOn
|
7 |
Tugnoli V, Capone JG, Eleopra R, Quatrale R, Sensi M, Gastaldo E, Tola MR, Geppetti P. Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin. Pain 2007; 130: 76-83.
DOI
|
8 |
Simone DA, Alreja M, LaMotte RH. Phychophysical studies of the itch sensation and itchy skin ('alloknesis') produced by intracutaneous injection of histamine. Somatosens Mot Res 1991; 8: 271-279.
DOI
ScienceOn
|
9 |
Stander S, Schmelz M. Chronic itch and pain--similarities and difference. Eur J Pain 2006; 10: 473-478.
DOI
ScienceOn
|
10 |
Schlereth T, Birklein F, Haack K, Schiffmann S, Kilbinger H, Kirkpatrick CJ, Wessler I. In vivo release of non-neuronal acetylcholine from the human skin as measured by dermal microdialysis: effect of botulinum toxin. Br J Pharmacol 2006; 147: 183-187.
DOI
ScienceOn
|
11 |
Gnirs K, Prelaud P. Cutaneous manifestations of neurological diseases: review of neuro-pathophysiology and diseases causing pruritus. Vet Dermatol 2005; 16: 137-146.
DOI
ScienceOn
|
12 |
Shaari CM, Wu BL, Biller HF, Chuang SK, Sanders I. Botulinum toxin decreases salivation from canine submandibular glands. Otolaryngol Head Neck Surg. 1998; 118: 452-457.
|
13 |
Rybnicek J, Lau-Gillard PJ, Harvey R, Hill PB. Further validation of a pruritus severity scale for use in dogs. Vet Dermatol 2009; 20: 115-122.
DOI
ScienceOn
|
14 |
Plant JD. Repeatability and reproducibility of numerical rating scales and visual analogue scales for canine pruritus severity scoring. Vet Dermatol 2007; 18: 294-300.
DOI
ScienceOn
|
15 |
Greaves MW. Recent advances in pathophysiology and current management of itch. Ann Acad Med Singapore 2007; 36: 788-792.
|
16 |
Hallett M. How does botulinum toxin work? Ann Neurol 2000; 48: 7-8.
DOI
ScienceOn
|
17 |
Davidson S, Zhang X, Yoon CH, Khasabov SG, Simone DA, Giesler GJ Jr. The itch-producing agents histamine and cowhage activate separate populations of primate spinothalamic tract neurons. J Neurosci. 2007; 27: 10007-10014.
DOI
ScienceOn
|
18 |
Rosser EJ Jr. Advances in the diagnostic and treatment of atopy. Vet Clin North Am Small Anim Pract 1999; 29: 1437-1447.
DOI
|
19 |
Morris JL, Jobling P, Gibbins IL. Botulinum neurotoxin A attenuates release of norepinephrine but not NPY from vasoconstrictor neurons. Am J Physiol Heart Circ Physiol 2002; 283: H2627-2635.
DOI
|
20 |
Oeconomou A, Madersbacher H. Botulinum neurotoxin A for benign prostatic hyperplasia. Curr Opin Urol 2010; 20:28-36.
DOI
ScienceOn
|
21 |
Arezzo JC. Possible mechanism for the effects of botulinum toxin on pain. Clin J Pain 2002; 18: S125-132.
DOI
|
22 |
Braune C, Erbguth F, Birklein F. Dose thresholds and duration of the local anhidrotic effect of botulinum toxin injection: measured by sudometry. Br J Dermatol 2001; 144: 111-117.
DOI
ScienceOn
|
23 |
Ishikawa H, Mitsui Y, Yoshitomi T, Mashimo K, Aoki S, Mukuno K, Shimizu K. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscle. Jpn J Opthalmol 2000; 44: 106-109.
DOI
ScienceOn
|
24 |
Favrot C, Linek M, Mueller R, Zini E. Development of a questionnaire to assess the impact of atopic dermatitis on health-related quality of life of affected dogs and their owners. Vet Dermatol 2010; 21: 63-69.
|
25 |
Marsella R, Nicklin CF. Intradermal skin test reactivity to histamine and substance P is blunted in dogs with atopic dermatitis. Vet Dermatol 2001; 12: 149-154.
DOI
ScienceOn
|
26 |
Carr MN, Torres SM, Koch SN, Reiter LV. Investigation of the pruritogenic effects of histamine, serotonin, tryptase, substance P and inteleukin-2 in healthy dogs. Vet Dermatol 2009; 20: 105-110.
DOI
ScienceOn
|
27 |
Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004; 107: 125-133.
DOI
|
28 |
Meyer-Lindenberg A, Wohlfarth KM, Switzer EN. The use of botulinum toxin A for treatment of possible essential blepharospasm in a dog. Aust Vet J 2003; 81: 612-614.
DOI
ScienceOn
|
29 |
Rossbach K, Stark H, Sander K, Leurs R, Kietzmann M, Baumer W. The histamine recepter as new target for treatment of canine inflammatory skin disease. Vet Dermatol 2009; 20: 555-561.
DOI
|
30 |
Giannantoni A, Rossi A, Mearini E, Del Zingaro M, Porena M, Berardelli A. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy. J Urol 2009; 182: 1453-1457.
DOI
ScienceOn
|
31 |
Lin AT, Yang AH, Chen KK. Effects of botulinum toxin A on the contractile function of dog prostate. Eur Urol 2007; 52: 582-589.
DOI
ScienceOn
|
32 |
Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005; 26: 785-793.
DOI
ScienceOn
|
33 |
Wollina U, Karamfilov T. Adjuvant botulinum toxin A in dyshidrotic hand eczema: A controlled prosepctive pilot study with left-right comparison. J Eur Acad Dermatol Venereol 2002; 16: 40-42.
DOI
ScienceOn
|
34 |
Hundley JL, Carroll CL, Lang W, Snively B, Yosipovitch G, Feldman SR, Jorizzo JL. Cutaneous sympton of dermatomyositis significantly impact patient's quality of life. J Am Acad Dermatol 2006; 54: 217-220.
DOI
ScienceOn
|
35 |
Heyer G, Vogelgsang M, Hornstein OP. Acetylcholine is an inducer of itching in patients with atopic eczema. J Dermatol 1997; 24: 621-625.
DOI
|
36 |
Huang W, Foster JA, Rogachefsky AS. Phrmacology of botulinum toxin. J Am Acad Dermatol 2000; 43: 249-259.
DOI
|
37 |
Hensel P, Austel M, Medleau L, Zhao Y, Vidyashankar A. Determination of threshold concentrations of allergens and evaluation of two different histamine concentrations in canine intradermal testing. Vet Dermatol 2004; 15: 304-308.
DOI
ScienceOn
|
38 |
Gazerani P, Pedersen NS, Drewes AM. Arendt-Nielsen L. Botulinum toxin type A reduces histamine-induced itch and vasomotor responses in human skin. Br J Dermatol 2009; 161: 737-745.
DOI
ScienceOn
|
39 |
Heyer G, Hornstein OP, Handwerker HO. Reaction to intradermally injected substance P and topically applied mustard oil in atopic dermatitis patients. Acta Derm Venereol 1991; 71: 291-295.
|
40 |
Han SK, Mancino V, Simon MI. Phospholipase Cbeta 3 mediates the scratching response activated by histamine H1 receptor on C-fibre nociceptive neurons. Neuron 2006; 52: 691-703.
DOI
ScienceOn
|
41 |
Wollina U, Konrad H, Peterson S. Botulinum toxin in dermatology-beyond winkles and sweat. J Cosmet Dermatol 2005; 4: 223-227.
DOI
ScienceOn
|
42 |
Yosipovitch G, Greaves MW, Schmelz M. Itch. Lancet 2003; 361: 690-694.
DOI
ScienceOn
|
43 |
Heckmann M, Heyer G, Brunner B, Plewig G. Botulinum toxin type A injection in the treatment of lichen simplex: An open pilot study. J Am Acad Dermatol 2002; 46: 617-619.
DOI
ScienceOn
|